Apixaban Efficacy, Safety Evaluated in AF Patient on Multiple Concomitant Medications
Older patients, females, and those with comorbidities were more likely to be on multiple medications.
AHA 2015
Apixaban vs. Warfarin: Effects Compared in AF Patients With, Without PAD
Researchers conducted a post hoc analysis of the ARISTOTLE trial which included patients with atrial fibrillation (AF) and a risk of stroke treated with either apixaban or warfarin for the prevention of stroke/ systemic embolism.
Isosorbide Mononitrate Did Not Up Exercise Tolerance in HF Patients
Patients were randomized to either 6 weeks of placebo first followed by 6 weeks of isosorbide mononitrate or 6 weeks of isosorbide mononitrate followed by 6 weeks of placebo.
Efficacy of Vericiguat Studied in Chronic HF Patients
Vericiguat an investigational oral sGC (soluble guanylate cyclase) stimulator.
Study Compares Safety, Efficacy of Pradaxa vs. Warfarin for Reducing Stroke, Major Bleeding Risk
The new findings were based on data from a pooled analysis of two large U.S. commercial health insurance databases.
Study Provides Insight into Antithrombotic Tx Reintroduction After Dabigatran Reversal
Idarucizumab (Praxbind) was recently granted accelerated approval as a reversal agent for patients on Pradaxa during emergency situations.
Staying on Brilinta Tx Improves CV Outcomes, Study Finds
The Food and Drug Administration (FDA) recently approved a new 60mg dosage strength for Brilinta to be used in patients with a history of MI beyond the first year.
New Data Support Sustained Antiplatelet Effects With Durlaza
New Haven Pharmaceuticals announced new data that demonstrates Durlaza (aspirin) extended-release capsules provide sustained antiplatelet control for a full 24-hour period in high-risk patients.
Entresto Cuts Hospital Readmissions in HF Patients
PARADIGM-HF study, which included 8,442-patients, is the largest clinical trial ever conducted in heart failure.
Jardiance Reduced CV Risk Regardless of Baseline HF Status
Jardiance, a sodium-glucose co-transporter 2 inhibitor, is indicated as adjunct to diet and exercise to improve glycemic control in adults with T2D.
